Search IPOs
SYMBIOTEC · NSE,BSE · Pharmaceuticals
Symbiotec Pharmalab IPO listed on 01 Sep 2026 on NSE,BSE at ₹988.00, a gain of 0.00% over the issue price of ₹988.00. The IPO was subscribed 75.05x overall.
Symbiotec Pharmalab IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 24 Aug 2026 |
| IPO Close Date | 27 Aug 2026 |
| Basis of Allotment | 28 Aug 2026 |
| Initiation of Refunds | 31 Aug 2026 |
| Credit of Shares to Demat | 31 Aug 2026 |
| Listing Date | 01 Sep 2026 |
Listing day gain
+0%
Listed at ₹988 (issue ₹988)
Issue
₹988
Listing
₹988
Current
₹1,097.7
+11.1% vs issue
Day range
₹934.2 – ₹1,180
Issue Size
17,786,442 shares
(aggregating up to ₹1,757.00 Cr)
Issue Price
₹938 – ₹988
Face Value
₹2/share
Market Lot
15 shares
Retail Min Investment
₹14,820
Listing At
NSE,BSE
Sale Type
both
Fresh Issue
1,521,261 shares
(aggregating up to ₹150 Cr)
Offer for Sale
16,265,181 shares
(aggregating up to ₹1,607 Cr)
Issue Type
book building
Open Date
24 Aug
Close Date
27 Aug
Allotment
28 Aug
Listing
01 Sep
Last updated: 1 month ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 31 Aug 2026 Latest | ₹988 | ₹200 | ₹1,188 | ₹200 |
20.24%
|
5:21 PM |
| 31 Aug 2026 | ₹988 | ₹205 | ₹1,193 | ₹205 |
20.75%
|
4:50 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 27 Aug 2026
| Category | Subscribed (x) |
|---|---|
| QIB | 181.2x |
| NII | 77.55x |
| bNII (bids above ₹10L) | 87.34x |
| sNII (bids below ₹10L) | 57.98x |
| Retail Investors | 13.65x |
| Employees | 16.28x |
| Total | 75.05x |
Showing the latest subscription snapshot.
View full subscription historyAnil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP are the promoters of the company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹192,660 |
| S-HNI (Min) | 14 | 210 | ₹207,480 |
| S-HNI (Max) | 67 | 1,005 | ₹992,940 |
| B-HNI (Min) | 68 | 1,020 | ₹1,007,760 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 8,876,517 (49.90%) |
|
•
Anchor Investor Shares Offered
|
5,325,909 (29.94%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
3,550,608 (19.96%) |
| NII (HNI) Shares Offered | 2,662,955 (14.97%) |
|
•
bNII > ₹10L
|
1,775,303 (9.98%) |
|
•
sNII < ₹10L
|
887,652 (4.99%) |
| Individual Investors Shares Offered | 6,213,562 (34.94%) |
| Employees Shares Offered | 33,408 (0.19%) |
| Total Shares Offered | 17,786,442 (100.00%) |
Established in 2002 by Anil Satwani, Symbiotec Pharmalab Limited has evolved over more than two decades into a major research-driven player in the global pharmaceutical ecosystem. Headquartered in Indore, Madhya Pradesh, the company specializes in developing and manufacturing high-quality Active Pharmaceutical Ingredients (APIs), focusing primarily on corticosteroids and steroidal hormones.
The operational core of Symbiotec is built around two large-scale, backward-integrated manufacturing units near Indore. These plants boast a chemical synthesis capacity of over 580 metric tonnes alongside a 300-kiloliter fermentation setup, allowing the company to manage complex organic chemistry and biotechnology platforms under one umbrella. Its strong commitment to quality compliance has earned it crucial clearances from premier regulatory bodies like the US FDA and EU-GMP, enabling the brand to supply life-saving ingredients across more than 65 global markets.
Financially, the company shows significant strength, recording total revenue of ₹756 crore and an EBITDA of ₹206 crore for Fiscal 2025. Backed heavily by private equity firms like Rosewood Investments and Motilal Oswal's India Business Excellence Fund, Symbiotec has officially taken its next public step. The firm filed its Draft Red Herring Prospectus (DRHP) with SEBI for a ₹2,180 crore mainboard IPO to list on the NSE and BSE. By balancing scientific precision with manufacturing scale, Symbiotec continues to cement its role as an essential supplier to the global healthcare and wellness industries.
Standalone · ₹ in Crores
| Particulars | FY Mar 2024 | FY Mar 2025 | FY Mar 2026 |
|---|---|---|---|
| Total Revenue | 723.33 | 755.98 | 872.26 |
| Profit After Tax (PAT) | 100.06 | 96.79 | 109.9 |
| EBITDA | 177.04 | 206.11 | 231.97 |
| Total Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Net Worth | 720.68 | 821.15 | 1,158.64 |
| Reserves & Surplus | 703.91 | 803.77 | 1,145.95 |
| Total Borrowing | 247.21 | 540.92 | 387.91 |
Revenue & Profit Trend
Key ratios per fiscal period
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| RoE Return on Equity Shows how much profit the company makes on the money shareholders have put in. 15% to 20% is healthy in most industries. | 12.66% | 11.19% |
| RoCE Return on Capital Employed Shows the profit earned on all the money used, shareholder funds plus loans. Matters most for factory and infrastructure heavy companies. | 11.8% | 11.56% |
| RoNW Return on Net Worth Shows the profit earned on the company's own net worth. Steady or rising over 3 years is a good sign. | 11.79% | 9.48% |
| PAT Margin Profit After Tax Margin Out of every ₹100 of sales, how much the company keeps after paying all costs, loan interest and tax. | 12.8% | 12.6% |
| EBITDA Margin Earnings Before Interest, Tax, Depreciation and Amortisation Margin Profit from the main business as a share of sales, before loan interest and tax. Compare it with other companies in the same industry. | 27.26% | 26.59% |
| P/BV Price to Book Value Tells you if the IPO price is above what the company actually owns. 1x to 3x is usually seen as reasonable. | 6.58x | 5.35x |
Issue-level · at the upper price band
| Particulars | Pre-IPO | Post-IPO |
|---|---|---|
| EPS Earnings Per Share Profit the company earns on each share. Post-IPO EPS is usually lower because the issue adds new shares. | ₹17.82 | ₹17.39 |
| P/E Price to Earnings Tells you if the IPO price is fair for what the company earns. Compare it with listed companies in the same sector. | 55.44x | 56.81x |
| Market Cap Market Capitalisation What the whole company is valued at, at the upper price band. Post-IPO counts the new shares the issue creates. | ₹6,094 Cr | ₹6,244 Cr |
The basis of allotment for Symbiotec Pharmalab IPO was finalised on 28 Aug 2026. You can check your allotment status using your PAN number or application number on the MUFG Intime India Pvt.Ltd portal or BSE.
The Symbiotec Pharmalab IPO is expected to open in Aug 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Symbiotec Pharmalab IPO is ₹938.00 - ₹988.00 per share.
As per market sources, Symbiotec Pharmalab IPO GMP is currently ₹200.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Symbiotec Pharmalab IPO stands at 75.05x overall.
The listing date for Symbiotec Pharmalab IPO is 01 Sep 2026.
No comments yet. Be the first to comment!
